drugset / Trial / NCT02035020

A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients

NCT02035020

Phase 2 Completed 10 enrolled Azienda Policlinico Umberto I
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to investigate whether the treatment with IFN gamma can induce significant accumulation of frataxin in FRDA patients, a possibility suggested by pre-clinical evidence in an animal model of the disease.

Timeline

Start
2013-05
Primary completion
2014-07-30
Completion
2014-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon gamma-1b Protein / enzyme biologic 200 ug Subcutaneous

Indications